Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TYNADOTE + n-acetylcysteine is a combination product that includes TYNADOTE, which is itself a branded formulation of acetylcysteine (N-acetylcysteine, NAC), a small molecule medication. Acetylcysteine is primarily a mucolytic agent and is widely used as the specific antidote for acetaminophen (paracetamol) overdose, mediating its effect predominantly by replenishing levels of glutathione in the liver, thus preventing or mitigating hepatic injury. It also exerts antioxidant, anti-inflammatory, and mucolytic effects, with clinical applications in conditions such as chronic obstructive pulmonary disease (COPD), contrast-induced nephropathy, and certain fibrotic and inflammatory diseases[1][2][3][4][5]. The exact formulation, dosing, and regulatory status of TYNADOTE as a distinct branded product may vary by jurisdiction; in the context above, it is treated as synonymous with an acetylcysteine preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TYNADOTE + n-acetylcysteine.